GO
Loading...

Midday movers: Las Vegas Sands, Deere, GM & more

Take a look at some of Wednesday's midday movers:

CGI Group fell on reports short-seller James Chanos has taken a large short position in the stock. The company is the main contractor behind the glitch-plagued healthcare.gov website.

Las Vegas Sands rose after Standard and Poor's raised its credit rating on the gaming operator to BBB- from BB .

Deere gained as the company expanded its share buyback program by $8 billion.

CF Industries hit a record high on reports the potash maker is considering a master-limited partnership, which are structured to pay cash to unit holders.

Nucor rose after the steel maker increased its quarterly dividend to 37 cents a share.

General Motors gained. CNBC's David Faber reported Kyle Bass' Hayman Capital took a stake in the automaker.

Twitter, Facebook and Linkedin led a mini-rally in social media stocks.

BRE Properties jumped on a report it might have received a $5 billion offer from rival Essex Property Trust. Fellow REITS Avalonbay Communities, Equity Residential and Simon Property Group were higher as well.

Intuitive Surgical fell following a recall involving its robot surgery system.

Oculus Innovative Sciences soared after the FDA approved the company's anti-scar treatment.

OmniVision Technologies declilned after the chip manufacturer forecast current-quarter revenue below street estimates.

Amazon rose after reporting record Kindle sales over the holiday weekend.

Hewlett-Packard gained after The Guardian reported it plans to cut more than 1,000 jobs in the U.K.

Pandora rose after the internet-radio company said its listeners increased in November by 16 percent from a year ago.

China Mobile gained after being granted permission to operate a fourth-generation mobile-telecommunications business network in China.

AutoNation popped on strong November auto sales.

Owens & Minor lost ground on news it sees fiscal 2014 earnings at the low end of expectations.

OncoMed rose as Jeffries raised its price target on the biotech company to $46 from $27, saying its deal with Celgene on Tuesday validates its drug pipeline. The stock surged yesterday on that deal.

Teradata fell after Morgan Stanley cut its rating on the data analytic firm to underweight from equal weight.

(Read More: See CNBC's Market Insider Blog)

—By CNBC's Rich Fisherman.

Questions? Comments? Email us at marketinsider@cnbc.com

  • Patti Domm

    Patti Domm is CNBC Executive Editor, News, responsible for news coverage of the markets and economy.

  • A CNBC reporter since 1990, Bob Pisani covers Wall Street from the floor of the New York Stock Exchange.

  • CNBC Personal Finance Correspondent

  • JeeYeon Park is a writer for CNBC.com. Follow her on Twitter: @JeeYeonParkCNBC

  • Rick Santelli joined CNBC Business News as an on-air editor in 1999, reporting live from the floor of the Chicago Board of Trade.

  • Senior Producer at CNBC's Breaking News Desk.